12,757 Shares in PROCEPT BioRobotics Co. (NASDAQ:PRCT) Purchased by Headlands Technologies LLC

Headlands Technologies LLC purchased a new stake in PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 12,757 shares of the company's stock, valued at approximately $1,027,000.

Other institutional investors also recently bought and sold shares of the company. Raleigh Capital Management Inc. purchased a new position in shares of PROCEPT BioRobotics in the 4th quarter valued at about $32,000. Signaturefd LLC increased its stake in PROCEPT BioRobotics by 26.7% in the fourth quarter. Signaturefd LLC now owns 689 shares of the company's stock valued at $55,000 after purchasing an additional 145 shares during the last quarter. IFP Advisors Inc acquired a new stake in PROCEPT BioRobotics during the fourth quarter worth approximately $58,000. Arcadia Investment Management Corp MI purchased a new stake in shares of PROCEPT BioRobotics during the 4th quarter worth approximately $64,000. Finally, Wilmington Savings Fund Society FSB purchased a new stake in shares of PROCEPT BioRobotics during the 3rd quarter worth approximately $64,000. 89.46% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. Morgan Stanley dropped their target price on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 26th. Truist Financial reiterated a "buy" rating and set a $90.00 target price (down previously from $105.00) on shares of PROCEPT BioRobotics in a research report on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $94.29.

PROCEPT BioRobotics Stock Performance

Shares of NASDAQ:PRCT traded down $0.78 on Monday, reaching $50.45. The company's stock had a trading volume of 616,284 shares, compared to its average volume of 762,833. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.02 and a quick ratio of 5.07. PROCEPT BioRobotics Co. has a 52-week low of $46.99 and a 52-week high of $103.81. The stock's 50-day moving average is $63.77 and its two-hundred day moving average is $76.92. The stock has a market capitalization of $2.77 billion, a P/E ratio of -25.50 and a beta of 1.09.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.01). PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. The company had revenue of $68.24 million for the quarter, compared to analyst estimates of $66.79 million. As a group, sell-side analysts forecast that PROCEPT BioRobotics Co. will post -1.75 EPS for the current year.

Insider Buying and Selling

In other news, CEO Reza Zadno sold 5,475 shares of the business's stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total transaction of $312,403.50. Following the transaction, the chief executive officer now directly owns 173,070 shares in the company, valued at $9,875,374.20. The trade was a 3.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Kevin Waters sold 733 shares of the firm's stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total transaction of $41,824.98. Following the completion of the sale, the chief financial officer now owns 107,991 shares of the company's stock, valued at approximately $6,161,966.46. The trade was a 0.67 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 6,455 shares of company stock valued at $368,322 over the last three months. 17.40% of the stock is currently owned by company insiders.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).